Sign in
4

Changes in Ownership

NEKTAR THERAPEUTICS Filed Acc 0000950170-24-062645

Chief R&D Officer sold 7,355 shares at $1.75 ($12,871)

From the SEC's structured data for this filing

Trades in this filing

Zalevsky Jonathan · Chief R&D Officer

Table I: Non-derivative

1 line
Date Transaction Shares Price Value Owned after D/I
2024-05-17 Sale : show line 1 in the form −7,355 $1.75 $12,871 257,670 D
Open-market sales · 7,355 sh · avg $1.75 · $12,871
Loading xslF345X05/ownership.xml…